Chiesi USA

ELFABRIO

Manufacturer:

Chiesi USA

Elfabrio HCPCS:

J2508

HCPCS Code Descriptor:

Injection, pegunigalsidase alfa-iwxj, 1 mg

Category:

J Code

Elfabrio NDCs:

10122-0160-10, 10122-0160-05, 10122-0160-02

Primary Type:

Enzyme Replacement Therapy

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Elfabrio:

ELFABRIO is a Enzyme Replacement Therapy drug manufactured by Chiesi USA and administered via the Intravenous route of administration. The J Code: J2508 is aligned to the drug ELFABRIO.

Elfabrio is an injection used to treat Fabry disease. Fabry disease is a rare inherited disorder caused by a deficiency of an enzyme called alpha-galactosidase-A. People with Fabry disease are unable to break down a fatty substance called globotriaosylceramide (Gb3), which the body uses for energy. Thus, Gb3 builds up in the blood vessels and tissues, which can increase the risk of heart attack, stroke, or kidney failure. Other symptoms may include numbness or tingling in the extremities, intolerance to extreme heat or cold, pain during physical activity, dizziness, and flu-like symptoms.

ACCESS PRICING AND MORE BY REGISTERING

J2508 Added Date:

January 1, 2024

J2508 Effective Date:

January 1, 2024

J2508 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Elfabrio billing and coding information.
Elfabrio patient assistance information can be found through Chiesi Total Care at the URL: https://chiesitotalcare.com/
ELFABRIO prescribing information can be found at the link below:
Information regarding ELFABRIO’s side effects can be found at MedlinePlus